• AstraZeneca published its ESMO 2026 presentation, reporting Phase III results across bladder, lung and gastric cancers.
• VOLGA showed Imfinzi with enfortumab vedotin improved event-free survival versus control, with a hazard ratio of 0.51; overall survival improved significantly.
• SAFFRON showed Tagrisso with Orpathys increased median overall survival to 17.8 months versus 12.9 months with platinum-pemetrexed.
• DeLLphi-305 showed maintenance Imfinzi with Imdelltra reduced the risk of death by 58% versus Imfinzi alone in extensive-stage small-cell lung cancer.
• CLARITY-Gastric01 showed sone-ve reduced mortality risk by 42% in second-line or later treatment; centrally assessed progression-free survival did not reach statistical significance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.